[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 1997

Improvement of Psoriasis Vulgaris With Oral Nickel Dibromide

Arch Dermatol. 1997;133(5):661-663. doi:10.1001/archderm.1997.03890410125024

A possible connection between nickel and the pathogenesis of psoriasis is indicated in at least 2 diverse studies.1,2 Bromide absorption has been proposed as a beneficial factor in psoriasis treatment at the Dead Sea, and bromide salts were found to have an antiproliferative effect on cell growth in cultures.3 A pilot study was designed to evaluate the effect of oral nickel and bromide therapy on psoriasis vulgaris.

Subjects and Methods.  This was a 2-period (12 weeks in each period), placebo-controlled, crossover study with a 48-hour washout between periods (the biological half-life of serum nickel ranges from 11-28 hours).4 Patients were evaluated at baseline and every 4 weeks thereafter. Eligible patients with at least 5% body surface area of plaque-type psoriasis were recruited from the clinic (Steven A. Smith, MD, Dermatology PC, Tulsa, Okla) patient database. Patients were instructed to discontinue all psoriasis treatments at least 2 weeks